-
Mirion Q2 revenue up 19.7% to $266.8M; GAAP net income down 4.7% to $8.1M
Revenue $266.8M vs $222.9M YoY (+19.7%); GAAP net income $8.1M vs $8.5M (-4.7%).
-
Mirion Q1 revenue up 27.5% to $257.6M, orders surge 19-42%; reaffirms FY guidance, adj. EPS trimmed
Q1 revenue $257.6M (+27.5% YoY); GAAP net loss $3.4M vs $0.4M income; GAAP EPS -$0.01.
-
Mirion grants CEO Thomas Logan 2.5M performance stock options tied to relative TSR
Target award of 2,500,000 performance-vesting stock options; maximum 3,750,000 shares at 150% target.
-
Mirion Q4 revenue $277.4M (+9.1% YoY); guides FY2026 revenue growth 22-24%
Q4 GAAP net income $17.8M vs $15.9M; EPS $0.07 unchanged YoY.
-
Mirion refinances existing term loans with new $450M tranche maturing 2032
Amendment No. 6 creates $450M Replacement Term Loans maturing June 5, 2032, to repay all prior term loans.
-
Mirion Technologies completes Paragon Energy Solutions acquisition
Mirion completed acquisition of all membership interests of WCI-Gigawatt Intermediate Holdco, LLC, indirect parent of Paragon Energy Solutions.
-
Mirion Q3 revenue up 7.9% to $223.1M; GAAP net income turns positive at $3.1M; raises free cash flow guidance
Q3 revenue $223.1M (+7.9% YoY); GAAP net income $3.1M vs loss $14.0M; Adj EBITDA $52.4M (+14.7%).
-
Mirion closes $410M equity & $375M convertible debt offerings for Paragon acquisition
Common stock offering of 19,906,322 shares at $21.35/share, net proceeds ~$409.7M.
-
Mirion acquires Paragon Energy Solutions for $585M all-cash
Equity Purchase Agreement to acquire all outstanding equity of Paragon for $585M cash.
-
Mirion Q2 revenue up 7.6%, GAAP net income $8.5M, raises FY guidance
Revenue $222.9M (+7.6% YoY); GAAP net income $8.5M vs loss $12.0M in Q2 2024.
-
Mirion refinances $450M term loans with new 2032 tranche; improved pricing and covenant flexibility
New $450M Replacement Term Loans maturing June 5, 2032; proceeds refinance all existing term loans.
-
Mirion prices upsized $400M 0.25% convertible notes due 2030; repays $250M term loan
$400M aggregate principal (including $50M option exercise) of 0.25% convertible senior notes due 2030.
-
Mirion proposes $300M convertible notes due 2030, plans $450M term loan refinancing
Offering of $300M aggregate principal amount of Convertible Senior Notes due 2030; initial purchasers have option for additional $45M.
-
Mirion Q1 revenue up 4.9% to $202M; GAAP net income $0.4M vs loss; raises revenue guidance
Revenue $202.0M (+4.9% YoY); GAAP net income $0.4M vs net loss $26.5M in Q1 2024.
-
Mirion Q4 revenue $254M, GAAP net income $15.9M; reaffirms FY2025 guidance
Q4 revenue $254.3M (+10.4% YoY); GAAP net income $15.9M vs $14.5M loss in Q4 2023.
-
Mirion 2028 targets: ~$1.1B revenue, 30% Adj EBITDA margin; 2025 guidance: 5.5-7.5% organic growth
2028 targets: revenue ~$1.1B, Adj EBITDA margin ~30%, Adj FCF conversion ~60%.
-
Mirion Q3 revenue $206.8M (+8.2% YoY); updates FY guidance, narrows FCF range to $65-75M
Q3 revenue $206.8M (+8.2% YoY); GAAP net loss $14.0M ($0.07 loss per share); adjusted EPS $0.08 vs $0.05 YoY.
-
Mirion Q2 revenue up 5% to $207.1M; loss narrows; raises FY adj. EBITDA guide
Revenue $207.1M (+5% YoY); net loss $12.0M vs $28.4M; adjusted EBITDA $48.8M (+10.2%).
-
Mirion Technologies Reports Q1 2024 Revenue of $192.6M, Reaffirms Full-Year Guidance
Revenue increased 5.8% to $192.6M in Q1 2024 from $182.1M in Q1 2023.
-
Mirion redeems all public warrants at $0.10; exercise deadline May 20, 2024
Redemption price $0.10 per warrant; cash exercise price $11.50 per share.
-
Mirion Q4 2023 revenue up 5.7% to $230.4M, net loss narrows to $15.2M, guides 2024
Q4 revenue $230.4M, +5.7% YoY; net loss $15.2M vs $153.4M loss in Q4 2022 (90.1% improvement).
-
Mirion Q3 revenue up 18.8% to $191.2M; net loss narrows to $12.1M; reiterates FY guidance
Revenue $191.2M (+18.8% YoY); net loss $12.1M vs $47.1M loss in Q3 2022.
-
Mirion Q2 revenue up 12.2% to $197.2M; raises FY revenue growth guidance to 8-10%
Q2 revenue $197.2M (+12.2% YoY); net loss narrowed to $28.4M from $59.3M.
-
Selling stockholders offer 7M MIR shares at $7.65; company receives no proceeds
Secondary offering of 7,000,000 shares of Class A common stock at $7.65 per share.
-
Mirion Q1 revenue up 11.6% to $182.1M; net loss widens to $42.9M; reaffirms FY guidance
Revenue $182.1M (+11.6% YoY); net loss $42.9M vs $19.0M loss in Q1 2022.
-
Mirion raises $150M from T. Rowe Price at $8.75/share; updates 2023 adjusted FCF guidance to $58M-$78M
T. Rowe Price funds invest $150M for 17.14M shares at $8.75/share (closing price on Feb 17).
-
Mirion Q4 rev up 22.6% to $217.9M but GAAP net loss $159.7M; FY23 guidance: 6-9% growth
Q4 revenue $217.9M (+22.6% YoY); adjusted revenue growth 20.5%.
-
Mirion Q3 revenues up 11.5% to $160.9M; net loss widens to $50.4M
Q3 revenue $160.9M (+11.5% YoY); adjusted revenue growth 8.7%.
-
Mirion appoints Michael Rossi as Medical Group President; he joins from Novartis
Michael Rossi appointed President of Mirion Medical, reporting to CEO Tom Logan.